Compositions and methods for immunotherapy
US-2015376296-A1 · Dec 31, 2015 · US
Anti-Prostate Cancer Antibodies and Methods of Detection and Treatment of Prostate Cancer
US2016145347A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016145347-A1 |
| Application number | US-201514961152-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 7, 2015 |
| Priority date | Dec 16, 2009 |
| Publication date | May 26, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same.
First claim
Opening claim text (preview).
1 .- 21 . (canceled) 22 . An antibody or antibody functional fragment that binds to B-III dodecaosylceramide or B-IV tetradecaosylceramide; provided that the antibody is not F77 MAb. 23 . The antibody or antibody functional fragment of claim 22 wherein said antibody or antibody functional fragment competes for binding with F77 MAb. 24 . The antibody or antibody functional fragment of claim 23 wherein said antibody or antibody functional fragment competes for binding with F77 MAb to B-III dodecaosylceramide or B-IV tetradecaosylceramide. 25 .- 33 . (canceled)
Assignees
Inventors
Classifications
specific for metastasis · CPC title
Antibody-dependent cellular cytotoxicity [ADCC] · CPC title
Antineoplastic agents · CPC title
Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title
- C07K16/3069Primary
Reproductive system, e.g. ovaria, uterus, testes, prostate · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016145347A1 cover?
- Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same.
- Who is the assignee on this patent?
- Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification C07K16/3069. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu May 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).